EVENTS | VIEW CALENDAR
New PDAC research
SAN DIEGO—Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, recently published in the Journal of Visual Experiments the establishment and immunological characterization of pancreatic ductal adenocarcinoma (PDAC) orthotopic tumor homograft models.
PDAC research represents an area of high unmet medical need, the company says, as PDAC fails to respond to a range of cancer therapies, including immuno-oncology (IO) therapy, partially due to an abundant tumor microenvironment (TME), that protects tumor cells from treatment. The development of new therapeutic and combination strategies requires highly relevant preclinical models recapitulating the complexity of PDAC tumors including the TME.
The orthotopic PDAC homograft models developed in this publication are said to capture the morphology of human tumors with enriched stromal content which is more suitable for preclinical pharmacology evaluation. The publication demonstrates that the TME of orthotopic transplantation differs from common subcutaneous transplantation, and indicates that this approach could better mimic human PDAC, and be more predictive of IO treatment in patients which is also highly dependent on the TME.